Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...
Oppenheimer downgraded Nice (NICE) to Perform from Outperform without a price target The company’s organic cloud growth continues to ...
Peter Oppenheimer, Goldman Sachs chief global equity strategist, joins 'Money Movers' to discuss the expected economic ...
The Rock can always put a wildly positive spin on any of his movies, but his latest promotional clip takes the cake: he’s ...
Oppenheimer analyst Rick Schafer raised the firm’s price target on Nvidia (NVDA) to $175 from $150 and keeps an Outperform rating on the ...
Cillian Murphy didn’t read “Small Things Like These” looking for a film to do. He was simply a fan of the author, Claire ...
One key factor that we can’t ignore is the continuing boom in artificial intelligence. Advances in AI technology have boosted ...
In a report released today, Francois Brisebois from Oppenheimer maintained a Hold rating on Ovid Therapeutics (OVID – Research Report).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback